The agricultural and pharmaceutical company Bayer is expanding its functional genomics portfolio with an acquisition in the United States.

The Leverkusen-based Dax company announced on Wednesday that its biotech subsidiary Vividion Therapeutics would acquire the precision oncology platform Tavros Therapeutics, based in Durham, North Carolina. "The acquisition of Tavros is an important next step in our quest to accelerate the development of previously unaddressable targets to improve outcomes for patients with high unmet medical needs," said Jürgen Eckhardt, head of Business Development and Licensing for Bayer's Pharmaceuticals Division. "We have had a very productive relationship over the last two years and have seen the clear synergies between our platforms," said Eoin McDonnell, CEO and co-founder of Tavros. Financial terms were not disclosed.

(Report by Philipp Krach, edited by Ralf Banser. If you have any questions, please contact our editorial team at berlin.newsroom@thomsonreuters.com (for politics and economics) or frankfurt.newsroom@thomsonreuters.com (for companies and markets).)